Stockreport

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Therapeutics Ltd - American Depositary Shares  (ADXN) 
PDF Ad Hoc Announcement Pursuant to Art.?53 LR  Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical c [Read more]